These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 10074928)

  • 1. Expression of alternatively spliced mdm2 transcripts correlates with stabilized wild-type p53 protein in human glioblastoma cells.
    Kraus A; Neff F; Behn M; Schuermann M; Muenkel K; Schlegel J
    Int J Cancer; 1999 Mar; 80(6):930-4. PubMed ID: 10074928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abundant expression of spliced HDM2 in Hodgkin lymphoma cells does not interfere with p14(ARF) and p53 binding.
    Stürzenhofecker B; Schlott T; Quentin T; Kube D; Jung W; Trümper L
    Leuk Lymphoma; 2003 Sep; 44(9):1587-96. PubMed ID: 14565663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative and aberrant splicing of MDM2 mRNA in human cancer.
    Bartel F; Taubert H; Harris LC
    Cancer Cell; 2002 Jul; 2(1):9-15. PubMed ID: 12150820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pathway regulating MDM2 protein degradation can be altered in human leukemic cells.
    Pan Y; Haines DS
    Cancer Res; 1999 May; 59(9):2064-7. PubMed ID: 10232588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer.
    Sigalas I; Calvert AH; Anderson JJ; Neal DE; Lunec J
    Nat Med; 1996 Aug; 2(8):912-7. PubMed ID: 8705862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer.
    Lukas J; Gao DQ; Keshmeshian M; Wen WH; Tsao-Wei D; Rosenberg S; Press MF
    Cancer Res; 2001 Apr; 61(7):3212-9. PubMed ID: 11306511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoplasmically "sequestered" wild type p53 protein is resistant to Mdm2-mediated degradation.
    Zaika A; Marchenko N; Moll UM
    J Biol Chem; 1999 Sep; 274(39):27474-80. PubMed ID: 10488081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms.
    Matsumoto R; Tada M; Nozaki M; Zhang CL; Sawamura Y; Abe H
    Cancer Res; 1998 Feb; 58(4):609-13. PubMed ID: 9485008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 gene family p51(p63)-encoded, secondary transactivator p51B(TAp63alpha) occurs without forming an immunoprecipitable complex with MDM2, but responds to genotoxic stress by accumulation.
    Okada Y; Osada M; Kurata S; Sato S; Aisaki K; Kageyama Y; Kihara K; Ikawa Y; Katoh I
    Exp Cell Res; 2002 Jun; 276(2):194-200. PubMed ID: 12027449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein.
    Landers JE; Cassel SL; George DL
    Cancer Res; 1997 Aug; 57(16):3562-8. PubMed ID: 9270029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The MDM2-p53 interaction.
    Moll UM; Petrenko O
    Mol Cancer Res; 2003 Dec; 1(14):1001-8. PubMed ID: 14707283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of p53 stability by Mdm2.
    Kubbutat MH; Jones SN; Vousden KH
    Nature; 1997 May; 387(6630):299-303. PubMed ID: 9153396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation.
    Jin Y; Lee H; Zeng SX; Dai MS; Lu H
    EMBO J; 2003 Dec; 22(23):6365-77. PubMed ID: 14633995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The corepressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasome-mediated degradation.
    Zilfou JT; Hoffman WH; Sank M; George DL; Murphy M
    Mol Cell Biol; 2001 Jun; 21(12):3974-85. PubMed ID: 11359905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of p53 by Mdm2: fate is in the numbers.
    Shmueli A; Oren M
    Mol Cell; 2004 Jan; 13(1):4-5. PubMed ID: 14731389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypophosphorylation of Mdm2 augments p53 stability.
    Blattner C; Hay T; Meek DW; Lane DP
    Mol Cell Biol; 2002 Sep; 22(17):6170-82. PubMed ID: 12167711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation.
    Rodriguez MS; Desterro JM; Lain S; Lane DP; Hay RT
    Mol Cell Biol; 2000 Nov; 20(22):8458-67. PubMed ID: 11046142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDM2 and p21WAF1/CIP1, wild-type p53-induced proteins, are regularly expressed by Sternberg-Reed cells in Hodgkin's disease.
    Sánchez-Beato M; Piris MA; Martínez-Montero JC; García JF; Villuendas R; García FJ; Orradre JL; Martínez P
    J Pathol; 1996 Sep; 180(1):58-64. PubMed ID: 8943816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of deletion-mutant epidermal growth factor receptor is associated with altered genotoxic stress-provoked p53 mRNA induction in a human glioblastoma cell line.
    Halatsch ME; Schmidt U; Bötefür IC; Holland JF; Ohnuma T
    Anticancer Res; 2001; 21(1A):189-95. PubMed ID: 11299733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway.
    Brignone C; Bradley KE; Kisselev AF; Grossman SR
    Oncogene; 2004 May; 23(23):4121-9. PubMed ID: 15064742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.